In this context, the FDA approved another PD-1 inhibitor, namely, cemiplimab-rwlc (Libtayo), on February 22, 2021 for the first-line treatment of advanced non-small cell lung cancer (65) with high PD-L1 expression (tumor proportion score ≥ 50%); it was approved for either metastatic or locally advanced cases without EGFR, ALK, or ROS1 mutations. The gene discussed is CD274; the disease is neoplasm.